Table 2. Covariates for included studies in the network meta-analysis.
| Included trial | Treatment arm | Median age, y | Male, % | Stage IV, % | ECOG PS 0–1, % |
|---|---|---|---|---|---|
| Chen et al. (27) | Erlotinib 150 mg/day | 77a | 82.5a | 75.4a | 80.7a |
| Vinorelbine 60–80 mg/m2 | 77a | 80.4a | 82.1a | 73.2a | |
| Hoang et al. (25) | Paclitaxel 135 mg/m2 + cisplatin 75 mg/m2 | 63 | 72.8 | 87.9 | 91.7 |
| Gemcitabine 1,000 mg/m2 + cisplatin 75 mg/m2 | 63 | 72.8 | 87.9 | 91.7 | |
| Docetaxel 75 mg/m2 + cisplatin 75 mg/m2 | 63 | 72.8 | 87.9 | 91.7 | |
| Paclitaxel 225 mg/m2 + carboplatin AUC 6 | 63 | 72.8 | 87.9 | 91.7 | |
| Kubota et al. (28) | Docetaxel 60 mg/m2 + gemcitabine 1,000 mg/m2 + vinorelbine 25 mg/m2 | 64a | 73a | 83 a | 100 |
| Paclitaxel 225 mg/m2 + carboplatin AUC 6 | 65a | 69a | 83a | 100 | |
| Lilenbaum et al. (29) | Erlotinib 150 mg/day | – | 44a | 87a | 0 |
| Paclitaxel 200 mg/m2 + carboplatin AUC 6 | – | 55a | 86a | 0 | |
| Morabito et al. (30) (CAPPA-2) | Gemcitabine 1,200 mg/m2 | 63a | 82a | 93a | 0 |
| Gemcitabine 1,000 mg/m2 + cisplatin 60 mg/m2 | 63a | 82a | 93a | 0 | |
| Pirker et al. (31,32) | Cisplatin 80 mg/m2 + vinorelbine 25 mg/m2 | 60a | 71a | 94a | 81a |
| Gatzemeier et al. (33) | Cisplatin 80 mg/m2 + vinorelbine 25 mg/m2 + cetuximab 250 mg/m2 (starting dose 400 mg/m2) | 59a | 69a | 94a | 84a |
| Socinski et al. (34) | Nab-paclitaxel 100 mg/m2 + carboplatin AUC 6 | 60a | 75a | 79a | 99.4a |
| Paclitaxel 200 mg/m2 + carboplatin AUC 6 | 60a | 75a | 79a | 99.6a | |
| Spigel et al. (61) | Necitumumab 800 mg + paclitaxel 200 mg/m2 + carboplatin AUC 6 | 66 | 79.1 | 100 | 100 |
| Paclitaxel 200 mg/m2 + carboplatin AUC 6 | 65 | 77.2 | 100 | 100 | |
| Tan et al. (36) (GLOB-3) | Docetaxel 75 mg/m2 + cisplatin 75 mg/m2 | 62.1a | 76.4a | 84.8a | 100 |
| Vinorelbine (IV 30 mg/m2; oral 80 mg) + cisplatin 80 mg/m2 | 59.4a | 73.2a | 80.5a | 100 | |
| Thatcher et al. (14) (SQUIRE) | Gemcitabine 1,250 mg/m2 + cisplatin 75 mg/m2 | 62 | 84 | 100 | 91 |
| Necitumumab 800 mg/m2 + gemcitabine 1,250 mg/m2 + cisplatin 75 mg/m2 | 62 | 83 | 100 | 91 | |
| Treat et al. (37) | Gemcitabine 1,000 mg/m2 + carboplatin AUC 5.5 | 65.8 | 62.4 | 94.6 | 100 |
| Gemcitabine 1,000 mg/m2 + paclitaxel 200 mg/m2 | 65.8 | 62.4 | 94.6 | 100 | |
| Paclitaxel 225 mg/m2 + carboplatin AUC 6 | 65.8 | 62.4 | 94.6 | 100 | |
| Yoshioka et al. (38) (LETS Study) | Paclitaxel 200 mg/m2 + carboplatin AUC 6 | 65 | 86.4 | 54.2 | 100 |
| S-1 40 mg/day, days 1–14 + carboplatin AUC 5 | 66 | 87.3 | 63.6 | 100 |
a, from the overall study; not specific to the squamous subset. EGOC PS, Eastern Cooperative Oncology Group performance status; IV, intravenous.